Literature DB >> 9425527

Neurobiology of retinal dopamine in relation to degenerative states of the tissue.

M B Djamgoz1, M W Hankins, J Hirano, S N Archer.   

Abstract

Neurobiology of retinal dopamine is reviewed and discussed in relation to degenerative states of the tissue. The Introduction deals with the basic physiological actions of dopamine on the different neurons in vertebrate retinae with an emphasis upon mammals. The intimate relationship between the dopamine and melatonin systems is also covered. Recent advances in the molecular biology of dopamine receptors is reviewed in some detail. As degenerative states of the retina, three examples are highlighted: Parkinson's disease; ageing; and retinal dystrophy (retinitis pigmentosa). As visual functions controlled, at least in part, by dopamine, absolute sensitivity, spatial contrast sensitivity, temporal (including flicker) sensitivity and colour vision are reviewed. Possible cellular and synaptic bases of the visual dysfunctions observed during retinal degenerations are discussed in relation to dopaminergic control. It is concluded that impairment of the dopamine system during retinal degenerations could give rise to many of the visual abnormalities observed. In particular, the involvement of dopamine in controlling the coupling of horizontal and amacrine cell lateral systems appears to be central to the visual defects seen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425527     DOI: 10.1016/S0042-6989(97)00129-6

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  70 in total

1.  Retinal nerve changes in patients with tremor dominant and akinetic rigid Parkinson's disease.

Authors:  Mohammad Rohani; Arash Sefidkar Langroodi; Shadi Ghourchian; Khalil Ghasemi Falavarjani; Reza SoUdi; Gholamali Shahidi
Journal:  Neurol Sci       Date:  2012-06-03       Impact factor: 3.307

2.  Optical coherence tomography as a potential readout in clinical trials.

Authors:  Benjamin M Greenberg; Elliot Frohman
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

3.  Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG.

Authors:  Anja M Palmowski-Wolfe; Maria Timoner Perez; Stefanie Behnke; Gerhard Fuss; Martin Martziniak; Klaus W Ruprecht
Journal:  Doc Ophthalmol       Date:  2006-06-22       Impact factor: 2.379

4.  Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease.

Authors:  Ozgül Altintaş; Pervin Işeri; Berna Ozkan; Yusuf Cağlar
Journal:  Doc Ophthalmol       Date:  2007-10-26       Impact factor: 2.379

5.  Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study.

Authors:  Berna Evranos Ogmen; Nagihan Ugurlu; Sevgül Faki; Sefika Burcak Polat; Reyhan Ersoy; Bekir Cakir
Journal:  Int Ophthalmol       Date:  2021-01-22       Impact factor: 2.031

6.  Ionic dysregulatory phenotyping of pathologic retinal thinning with manganese-enhanced MRI.

Authors:  Bruce A Berkowitz; Marius Gradianu; Stephen Schafer; Ying Jin; Andre Porchia; Raymond Iezzi; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-24       Impact factor: 4.799

7.  Schizophrenia and the retina: Towards a 2020 perspective.

Authors:  Steven M Silverstein; Samantha I Fradkin; Docia L Demmin
Journal:  Schizophr Res       Date:  2019-11-07       Impact factor: 4.939

8.  Expression and subcellular location of alpha-synuclein during mouse-embryonic development.

Authors:  Shan-chuan Zhong; Xue Luo; Xing-shu Chen; Qi-yan Cai; Jing Liu; Xing-hua Chen; Zhong-xiang Yao
Journal:  Cell Mol Neurobiol       Date:  2009-11-03       Impact factor: 5.046

Review 9.  Dopamine and retinal function.

Authors:  Paul Witkovsky
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

Review 10.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.